Compare EH & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | NVAX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.5M | 1.6B |
| IPO Year | 2019 | 1996 |
| Metric | EH | NVAX |
|---|---|---|
| Price | $12.03 | $10.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $21.85 | $11.33 |
| AVG Volume (30 Days) | 494.7K | ★ 4.2M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $10.53 | N/A |
| Revenue Next Year | $81.37 | N/A |
| P/E Ratio | ★ N/A | $3.97 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $11.07 | $5.01 |
| 52 Week High | $25.48 | $11.85 |
| Indicator | EH | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 55.12 |
| Support Level | $11.15 | $7.81 |
| Resistance Level | $12.80 | $10.42 |
| Average True Range (ATR) | 0.55 | 0.73 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 39.08 | 36.18 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.